Michel Bazinet, M.D.
CEO & Chief Medical Officer
Dr. Bazinet is responsible for the development strategy of the Company, and oversees all operations, including the planning of clinical trials. Previously, Dr. Bazinet worked as assistant professor in the departments of Urology and Oncology at McGill University in Montreal. He did his medical training at Sherbrooke University, his urology training at McGill University after which he did a 3-year fellowship in human tumor immunology and urologic oncology at the Memorial Sloan-Kettering Cancer Center in New York from 1984 to 1987. In 1996 Dr. Bazinet founded Mediconsult, and was the Medical Director when it listed on NASDAQ in 1999. Dr. Bazinet has previously served as a member of the board of directors for 2 public companies and has been a consultant for many biotechnology projects.
Andrew Vaillant, Ph.D.
Chief Scientific Officer
Dr. Vaillant has more than 15 years of experience in the fields of nucleic acid chemistry, virology and drug development and is the discoverer of Replicor’s NAP technology. He oversees all intellectual property, regulatory, manufacturing and research and development activities at Replicor. He also plays a key role in the design, conduct and oversight of clinical trials and oversees all clinical data analysis. He has authored numerous publications and patents on the use of NAPs in various infectious diseases. Dr. Vaillant also actively contributes in policy forums focused on accelerating the approval of novel antiviral therapies for HBV infection. He also serves on several working groups devoted to defining next generation approaches for assessing the antiviral efficacy and safety of novel combination therapies and to defining new approaches for determining functional control of HBV infection in clinical trials. He was a postdoctoral fellow at the Montreal Neurological Institute and holds a Ph.D. in Cell Biology from the University of Ottawa.
Matthieu Blanchet, Ph.D.
Director of Scientific Collaborations
Dr. Blanchet manages Replicor’s collaborations with external academic labs for the purposes of expanding our understanding the antiviral mechanisms of action of Replicor’s NAP compounds. Dr. Blanchet has 12 years of experience in investigating antiviral technologies targeting hepatitis C, hepatitis B and hepatitis delta viruses and on the functional interplay between the lifecycles of these hepatotropic viruses and cellular lipid metabolism. He was previously an associate-researcher at INRS-Institut Armand-Frappier (Laval, Quebec) and a postdoctoral fellow at the Institut Pasteur (Paris, France) where he studied flavivirus – host interactions. He obtained his Ph.D. in Virology from the INTS-Institut National de la Transfusion Sanguine (Paris, France) where he was mentored by the noted virologist Dr. Camille Sureau.
Léo Bazinet, B.A.A.
Mr. Bazinet has 30 years of experience in administration, marketing and finance in the private sector. He has a Bachelor’s Degree in Business Administration from the University of Quebec in Montreal.
Allen Tang, Ph.D.
V.P. Business Development
Dr. Allen Tang has nearly 20 years’ experience in corporate management, operations, business development and financing in the pharmaceutical, healthcare and life sciences industries; Dr. Tang is well-connected within these sectors.
Dr. Tang is currently the Managing Director at Shanghai Elite Choices LLC, a financial advisory firm serving both domestic and overseas clients in the healthcare sector. Previously, Dr. Tang was an investment director at Shenzhen-based CDF-Capital focusing on healthcare-related project investments. Prior to launching his investment career, Dr. Tang was the General Manager at Shanghai Promega Biological Products Co., Ltd., a joint venture between Shanghai Research Center of Biotechnology, Chinese Academy of Sciences and, the US-based life sciences conglomerate Promega Corporation. Dr. Tang was also the Director of Business Development and Regulatory Affairs at WuXi PharmaTech Inc. (NYSE: WX). Before returning to China, Dr. Tang worked as a Management Consultant for the Toronto-based SHI Consulting.
Dr. Tang studied Genetics at Fudan University, then transferred to the University of Kentucky where he received both a B.S. in Biotechnology and a Ph.D. in Pharmaceutical Sciences. Dr. Tang was subsequently a post-doctoral Research Fellow at Harvard Medical School. Later, Dr. Tang went on to obtain an M.B.A. from the Rotman School of Management, University of Toronto.